Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech Angel Investors in United Kingdom in April 2025

Last updated: Apr 2025 A list of 50 angel investors that invest in Biotech startups based in United kingdom. We rank investors based on the number of investments they made in Biotech companies from United kingdom. We update this investor list every month.

Top 50 Biotech Angel Investors in United Kingdom in April 2025

Investor	Biotech United Kingdom investments
Jonathan Milner	32
Nadav Rosenberg	5
Darrin Disley	4
Stefano Bernardi	3
Charlie Songhurst	3
Milad Alucozai	3
Jeff Dean	3
Ian Hogarth	3
Jude Gomila	3
Peder Nielsen	3
Bradley Horowitz	3
DrPano Kroko Churchill	3
Edward Lando	2
Gilad Engel	2
Nadav Ben-Chanoch	2
Chris Mairs	2
Paul Wicks	2
Ed Parkinson	2
Paul Forster	2
Tim Dempsey	2
Jon Oringer	2
Jon Oringer	2
Robert Kopple	2
Inaki Berenguer	2
Serge Chiaramonte	2
Jim Mellon	2
Patrick Pichette	2
Nick Boyle	2
Aidan Gomez	2
Jan Hruska	2
Hugh Grant	2
Mati Staniszewski	2
Ariel Poler	2
Jon Oringer	2
Mark Evans	2
Pratima Aiyagari	2
Nicholas Edwards	2
Aydın Öztunalı	1
Alice Zhang	1
David Ebsworth	1
Jon Moulton	1
Karl Wills	1
Nadav Ben-Chanoch	1
Bryan Meehan	1
Mark McCamish	1
Margaret Georgiadis	1
Vishal Rao	1
John Anthony Knight	1
Siddhant Jayakumar	1
Andrew J M Richards	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Spain

Portfolio highlights

Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
Epitopea — Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.
Exciting Instruments — Exciting Instruments Limited is a joint company founded in Sheffield that combines the software prowess of Bulldozer Limited with Dr. Timothy Craggs' knowledge of single molecules. Through the use of cloud connectivity and real-time data visualisation, we are a genuine science and software partnership on a mission to assist you in streamliningthe procedure for creating discoveries in biophysics, life sciences, drug discovery, and medical diagnostics.

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

Investment focus

Biotechnology, Artificial Intelligence, Pharmaceutical
Seed, Pre-Seed, Series A
United Kingdom, Israel, Singapore

Portfolio highlights

thymia — Making mental health as objectively measurable as physical health.
Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Loops — With Loops causal insights you can identify your biggest opportunities to maximize your KPIs... try the Loops way

Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.

Investment focus

Biotechnology, Health Care, Big Data
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.

Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.

Investment focus

Biotechnology, Software, Artificial Intelligence
Seed, Pre-Seed, Funding Round
United Kingdom, Italy, France

Portfolio highlights

Freatic — Building the monetization layer for your alpha
CaSRevolution — A novel disease-modifying approach against neurodegeneration
Automated Architecture — A global ecosystem of automated micro-factories, to deliver sustainable, affordable and beautiful architecture to millions of people.

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Pre-Seed, Funding Round
United Kingdom, United States, Germany

Portfolio highlights

FlyMy.AI — Real-time AI cloud
Lovable — Build software products, using only a chat interface
Briefcase — Briefcase automates the legwork in accounting so you can focus on growing your practice

Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Pre-Seed
United States, Canada, United Kingdom

Portfolio highlights

Arpeggio Bio — We engineer medicine based not on a single target, but the biological network as a whole.
Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.

Jeff Dean joined Google in 1999 and is currently a Google Senior Fellow in Google's Research Group, where he leads the Google Brain team, Google's deep learning research team in Mountain View, working on systems for speech recognition, computer vision, language understanding, and various predictive tasks. He has co-designed /implemented five generations of Google's crawling, indexing, and query serving systems, and co-designed / implemented major pieces of Google's initial advertising and AdSense for Content systems. He is also a codesigner and coimplementor of Google's distributed computing infrastructure, including the MapReduce, BigTable and Spanner systems, protocol buffers, LevelDB, and TensorFlow, a popular open-source system for machine learning.Jeff received a Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the Mark Weiser Award and the ACM-Infosys Foundation Award in the Computing Sciences.

Investment focus

Artificial Intelligence, Biotechnology, Information Technology
Seed, Series A, Pre-Seed
United States, Japan, Australia

Portfolio highlights

OpenInfer — OpenInfer develops an AI inference engine for edge applications
Workhelix — Workhelix is a developer of workforce management platform to assist with business management.
Yutori — Yutori is part of a slew of AI startups creating autonomous agents, or systems that use AI to perform actions on their own.

Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.

Investment focus

Software, E-Commerce, Internet
Seed, Pre-Seed, Series A
United Kingdom, United States, Germany

Portfolio highlights

Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
Unitary — We detect harmful content with context-aware AI to keep brands and platforms safe online.
Fabric — One home for your digital world. Your second brain. A file explorer and workspace for the internet age. All your drives, clouds, notes, screenshots, links, and files in one calm, minimal app. No organizing required. Never forget anything again.

Jude Gomila is currently CEO and Founder of the startup Golden.

Investment focus

Software, Biotechnology, Information Technology
Seed, Pre-Seed, Angel
United States, United Kingdom, Canada

Portfolio highlights

Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!

Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund

Investment focus

Biotechnology, Machine Learning
Seed, Funding Round
United Kingdom

Portfolio highlights

Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.

Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Series B
United States, United Kingdom, Germany

Portfolio highlights

Mill — Mill is the smartest device in your kitchen. Mill turns would-be food waste into resources for the Earth. Keep filling it for weeks.
Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
Overture Life — We are making In Vitro Fertilization (IVF) more accessible than ever before while improving success rates. An embryology lab in a box.

Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com

Investment focus

Health Care, Therapeutics, Biotechnology
Angel, Series A
United Kingdom

Portfolio highlights

Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....

Edward Lando is the founder of Pareto Holdings. He previously worked at Horizons School of Technology as a co-founder. Edward Lando attended the Wharton School.

Investment focus

Software, Health Care, Information Technology
Seed, Pre-Seed, Funding Round
United States, France, United Kingdom

Portfolio highlights

Volta — Our mission is to empower brands, wholesalers, and distributors with the tools and support to thrive in today's digital economy.
Swish Robotics — Embodied Intelligence for the Home
Workflow — A minimalist collaboration platform for creative teams. Manage tasks, get AI reviews, and share work, all in one place.

Gilad Engel

Investment focus

Hardware, Analytics, Biotechnology
Seed, Pre-Seed
France, Israel, United Kingdom

Portfolio highlights

Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Fourier Optics — Fourier optics creates meta-surface based optical systems for Augmented Reality glasses

Nadav Ben-Chanoch

Investment focus

Software, Information Technology, Health Care
Seed, Pre-Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

micro1 — We help companies hire and manage the best software engineers easily.
TRIVER — Triver develops online and digital tools to assist and support various financial services. It is based in London, England.
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.

Chris Mairs - Venture Partner @ Entrepreneur First

Investment focus

Software, FinTech, Financial Services
Seed, Pre-Seed, Angel
United Kingdom, United States

Portfolio highlights

VitVio — VitVio is a platform built around AI and computer vision with the goal of improving efficiency and quality of care in operating rooms.
Briefcase — Briefcase automates the legwork in accounting so you can focus on growing your practice
Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.

Paul is a neuropsychologist and expert in digital health, clinical trials, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 700,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul shaped the scientific validity of the platform in generatinginsights from patient-generated health data, leading to over 110 studies including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and methods for patient-centered and virtual clinical trial designs.He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease.His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.

Investment focus

Real Time, Marketplace, Biotechnology
Seed, Series A
United Kingdom

Portfolio highlights

Sano Genetics — Sano Genetics is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions. The company was founded in 2017 and is headquartered in Cambridge.

Ed Parkinson

Investment focus

Software, Health Care, Life Science
Seed
United Kingdom

Portfolio highlights

Antiverse — Designing biologics for 100 challenging targets

Paul Forster

Investment focus

Software, FinTech, Financial Services
Seed, Series A, Pre-Seed
United Kingdom, Germany, United States

Portfolio highlights

Stackfix — Stackfix operates as a software comparison platform.
Singulate — The early Hopin team (#1, #4, #30 are cofounders) are back together to solve the biggest problem they saw in events and marketing at Hopin. They’re building a next gen AI marketing platform called Singulate. Singulate provides the easiest way to do audience segmentation and better relevance-personalization for marketing to individuals at scale —results of up to 10X higher CTRs and 5X response rates. They’re helping marketers (in demand gen, growth, community/events) nurture and convert more pipeline from their events and existing customers - it’s not an AI cold outreach sales tool (although it can do reactivations) but rather a lifecycle growth marketing tool. The best personalization is invisible - this is the future of large-scale communication. Get a demo to see the product.
Purple Dot — Sell More by Selling Earlier

Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.

Investment focus

Software, SaaS, Information Technology
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

Lunio — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
PPC Protect — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media

Jon Oringer is the founder and chairman of Shutterstock.

Investment focus

Software, Information Technology, E-Commerce
Seed, Pre-Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

SLUSHY — Slushy is the ultimate adult social platform for new creators. Post content, grow your following, and monetize your profile all in one place. Reach new fans on day one with instant approvals and payouts on demand. Sign up and start earning today!
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Unsloth AI — Easy finetuning for AI and LLMs. Open-source and for beginners. Get faster with Unsloth.

Jon Oringer is the founder and chairman of Shutterstock.

Investment focus

Software, Information Technology, Health Care
Seed, Pre-Seed, Series A
United States, France, United Kingdom

Portfolio highlights

SLUSHY — Slushy is the ultimate adult social platform for new creators. Post content, grow your following, and monetize your profile all in one place. Reach new fans on day one with instant approvals and payouts on demand. Sign up and start earning today!
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Unsloth AI — Easy finetuning for AI and LLMs. Open-source and for beginners. Get faster with Unsloth.

Robert Kopple

Investment focus

FinTech, Finance, Life Science
Funding Round, Convertible Note
United States, United Kingdom

Portfolio highlights

Tradier — Tradier is a financial services cloud provider that offers a groundbreaking solution to serve platform providers, developers and investors. The Tradier solution features an innovative set of fully hosted APIs, modules, and "out of the box" tools that are leveraged by a growing list of providers.
ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.

Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.

Investment focus

E-Commerce, FinTech, Software
Seed, Angel, Pre-Seed
Spain, United States, United Kingdom

Portfolio highlights

Goin — Goin is a mobile application to save money easily and take advantage of it without knowing how to invest, through Machine Learning algorithms that allow you to accumulate the user's money through small daily gestures. he three Spanish founders, David, Carlos and Gabriel, were looking for a way to optimize their own money, and decided toconduct an experiment by exchanging their debit cards and thus saving 62% during those two months of rehearsal. This is how Goin emerged, which aims to meet the needs of 100% of Millennials, of which 83% confess that they do not know how to save, making available an easy-to-use tool that enhances their finances and lifestyle. On the one hand, the Barcelona startup allows the user to add money automatically and multiply it without having previous knowledge of investment. Goin uses a simple system that first asks to know the user through questions about their habits and, in this way, they are offered automatic systems and methods of saving. Once the user adds money to the app, they can transfer part or all of it to investment, or to their bank account. Its Smart Saving technology manages to accumulate money with small, everyday gestures, such as rounding a payment.
Bankflip — Permissioned data technology to collect and process your customers' income, tax, employment & other relevant data & documents in real-time
Mable (Neurolytic Healthcare) — Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.

Serge Chiaramonte

Investment focus

FinTech, Financial Services, Information Technology
Seed, Pre-Seed, Funding Round
United Kingdom, United States, France

Portfolio highlights

Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
qomodo — Qomodo: La piattaforma BNPL innovativa. Rate a tasso zero, approvazioni veloci, transazioni sicure. Rivoluzionaria nell'acquisto per aziende e consumatori.
Tranched — Introducing real-time on-chain securitisation. Fintech Lenders and Professional Investors can now launch an institutional-grade transaction up to 90% faster than before.

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.

Investment focus

Biotechnology, Food and Beverage, Health Care
Series A, Seed, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.

Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).

Investment focus

Artificial Intelligence, Software, Machine Learning
Seed, Series A, Series B
United Kingdom, Germany, United States

Portfolio highlights

Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
Kaedim — Kaedim’s product creates 3D content as easily as you can take a photo, 2D content, with your smartphone today.
Apheris — Build ML-powered products using data that spans organizational or geographical boundaries, while ensuring compliance with regulation.

In 2010, Nick founded Lightsource Renewable Energy, then just a six-person start-up, which quickly grew over 5 years to become Europe’s largest solar developer and operator and a recognised global leader. In his role as Group CEO, Nick’s dynamic leadership and vision has driven the company to tremendous success and in December 2017, Lightsourceannounced a strategic partnership with BP which has committed aggressively to accelerate the low carbon transition. The company has rebranded to Lightsource BP in affirmation of this powerhouse commitment which is set to shape the future of global energy delivery. Nick previously sat at Board and Senior Director level in a number of leading retail financial service companies. Throughout his career, Nick has always been recognised for his entrepreneurial skill and success in pairing retail financial products with low-risk, predictable investments.

Investment focus

Biofuel, Agriculture, Artificial Intelligence
Seed
United Kingdom

Portfolio highlights

Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.

Aidan Gomez is a Co-founder & CEO of Cohere. He attended University of Oxford.

Investment focus

Artificial Intelligence, Software, Information Technology
Seed, Pre-Seed
United States

Portfolio highlights

DatologyAI — DatologyAI optimize training efficiency, maximize performance and reduce compute costs with expert curation.
Latent Labs — Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today.
Helical — The full power of DNA & (m)RNA Bio Foundation Models in one open-core platform. Accelerate Drug Discovery with AI.

Jan Hruska

Investment focus

Medical, Health Care, Life Science
Seed, Funding Round
United Kingdom

Portfolio highlights

Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.

Hugh Grant is President and Chief Executive Officer at Monsanto.

Investment focus

Biotechnology, Machine Learning
Seed, Funding Round
United Kingdom

Portfolio highlights

Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.

Mati Staniszewski is the Co-Founder of ElevenLabs.

Investment focus

Software, Information Technology, Artificial Intelligence
Pre-Seed
United States

Portfolio highlights

Latent Labs — Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today.
Zeta Labs — Revolutionize daily tasks with our AI assistant. Not just a chatbot - it chats, understands, and performs. Free yourself to focus on meaningful things.

Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.

Investment focus

Software, Social Media, Internet
Seed, Series A, Angel
United States, Mexico, United Kingdom

Portfolio highlights

Goin — Goin is a mobile application to save money easily and take advantage of it without knowing how to invest, through Machine Learning algorithms that allow you to accumulate the user's money through small daily gestures. he three Spanish founders, David, Carlos and Gabriel, were looking for a way to optimize their own money, and decided toconduct an experiment by exchanging their debit cards and thus saving 62% during those two months of rehearsal. This is how Goin emerged, which aims to meet the needs of 100% of Millennials, of which 83% confess that they do not know how to save, making available an easy-to-use tool that enhances their finances and lifestyle. On the one hand, the Barcelona startup allows the user to add money automatically and multiply it without having previous knowledge of investment. Goin uses a simple system that first asks to know the user through questions about their habits and, in this way, they are offered automatic systems and methods of saving. Once the user adds money to the app, they can transfer part or all of it to investment, or to their bank account. Its Smart Saving technology manages to accumulate money with small, everyday gestures, such as rounding a payment.
Reloadly — Unlock global access with Reloadly's powerful API for digital gift cards and mobile top- ups.Simplify payouts, boost engagement, and grow your business with customizable, easy- to - integrate solutions.
Openlytics — Openlytics is a visual analytics platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape thedirection of the product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.

Jon Oringer is the founder and chairman of Shutterstock.

Investment focus

Software, Information Technology, E-Commerce
Seed, Pre-Seed, Funding Round
United States, France, United Kingdom

Portfolio highlights

SLUSHY — Slushy is the ultimate adult social platform for new creators. Post content, grow your following, and monetize your profile all in one place. Reach new fans on day one with instant approvals and payouts on demand. Sign up and start earning today!
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Unsloth AI — Easy finetuning for AI and LLMs. Open-source and for beginners. Get faster with Unsloth.

Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.

Investment focus

Software, E-Commerce, Health Care
Series A, Seed, Series C
United Kingdom, United States, The Netherlands

Portfolio highlights

ONI — Where are you in your super-resolution journey? ONI is here to support you along your super-resolution journey Answer a few simple questions to discover key resources that can help you make the most of single-molecule imaging technology across a wide range of applications Products Gallery FAQs Subscribe to our mailing list
Ufonia — Ufonia is replacing routine patient healthcare interactions with next-generation automated phone calls.
Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.

Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.

Investment focus

Analytics, Cyber Security, SaaS
Seed, Pre-Seed, Series A
United Kingdom, France, Croatia

Portfolio highlights

Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Mindflow — Mindflow is a No-Code & AI-driven Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks.
ESPROFILER — ESPROFILER uniquely combines security spend, commercials, and capabilities with threats helping security leaders maximise their investments.

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Investment focus

Medical, Health Care, Life Science
Seed, Funding Round
United Kingdom

Portfolio highlights

Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.

Aydın Öztunalı

Investment focus

Software, Apps, Mobile
Seed, Angel
Turkey, United States, United Kingdom

Portfolio highlights

Evreka — Evreka is a leading SaaS company providing the most comprehensive intelligent solutions designed for the entire category of waste management across the globe.
Initio — initio is Enabling the transformation of the pharmaceutical industry today by using lab-on-a-chip and organ-on-a-chip technologies
Otsimo — Otsimo offers special education and speech therapy apps for autism, down syndrome and other developmental disabilities. Click to see our autism apps!

CEO and Co-founder at Verge Genomics; Angel Investor in Tech-Enabled Bio

Investment focus

Health Care, Science/Engineering, Biotechnology
Seed, Series A, Pre-Seed
United States

Portfolio highlights

Encellin — Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Arpeggio Bio — Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work.

Dr. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr. Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s ExecutiveCommittee, positions he held until August 2014. Dr. Ebsworth received a PhD in industrial relations from the University of Surrey.

Investment focus

Pharmaceutical, Biopharma, Health Care
Seed, Post-IPO Equity
United Kingdom

Portfolio highlights

Small Pharma — Small Pharma applies expert intellectual property design to guide academic discovery to commercial product. We operate a scalable model of outsourced drug development. We assemble specific expert teams to design and execute development programs with demonstrated track-records in all disciplines essential to their success.
Verona Pharma — Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Jon Moulton is a British venture capitalist. He is the founder and managing partner of the private equity firm Better Capital, and is the former managing partner of the private equity firm Alchemy Partners.

Investment focus

Financial Services, FinTech, Banking
Funding Round, Seed, Series A
United Kingdom, Cyprus, Luxembourg

Portfolio highlights

Pockit — Open a prepaid account in 3 minutes online or in-app, get your contactless prepaid card in 2 working days with no credit check.
Hometree — Keep yourself warm with Hometree, and try our no price hike promise. Compare our different boiler & home cover plans to see how you can save.
Hellas Direct — Hellas Direct is a digital-first, full-stack insurance company, empowered by cutting-edge technology and artificial intelligence. The Cyprus-based company is backed by a roster of leading investors, including Portag3, IFC (a member of the World Bank), Endeavor Catalyst, former Goldman Sachs economist Lord O’Neill and private equity veteran JonMoulton. Modelling itself on Amazon, Hellas Direct aims to disrupt the insurance value chain by adopting an extreme focus on operational excellence.

Originally at MetaPack in 2000, Karl returned in November 2009 to take on the role as COO and CIO responsible for MetaPack’s Product Development, Support, Infrastructure and Carrier Integration. Karl is now responsible for handling MetaPack's legal activity and ensuring best practice is brought into all parts of the MetaPack operation toensure exceptional performance for our customers. In between the MetaPack roles, he worked for Abacus Billing as CEO before its sale to Mind CTI, successfully managing the company turnaround at Solution 1 as COO and interim CEO where he focused on improving their delivery function as well as their IT infrastructure.Prior to joining MetaPack that he has held roles such as Senior Supply Chain Director for EMI Records (based in The Netherlands), IT Director for EMI Operations and IT Director EMI France as well as a number of other UK and European IT and Logistics roles. This provides Karl with over 30 years experience in general management and the IT, logistics and warehouse industry.

Investment focus

CRM, Farming, Agriculture
Seed
United Kingdom

Portfolio highlights

Bionema — Bionema provides eco-friendly biocontrol solutions, helping farmers protect crops naturally while reducing chemical use for a healthier planet.

Nadav Ben-Chanoch - Partner @ Pareto Holdings

Investment focus

Software, FinTech, Information Technology
Seed, Pre-Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

Swaap — We we build & operate onchain trading systems.
micro1 — We help companies hire and manage the best software engineers easily.
Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.

Bryan Meehan is the Co-Founder of NUDE Skincare.

Investment focus

Biotechnology, Sustainability, Machine Learning
Seed, Angel, Series A
United States, United Kingdom, Estonia

Portfolio highlights

LOLIWARE — LOLIWARE is rewriting the story of destructive packaging. By harnessing the power of seaweed to replace plastic at scale, LOLIWARE is tapping into its potential to regenerate our ocean and decarbonize our planet.
Shellworks — Reimaging nature's packaging with beautifully sustainable, truly compostable alternatives to plastic for cosmetics and beauty products.
8B Education Investments — 8B African Education Investments helps African students succeed at global universities with tools, resources, and world-class support to master every step of their educational journey.

Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a SeriesB offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion.He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods.He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University

Investment focus

Medical, Biopharma, Biotechnology
Seed
United Kingdom

Portfolio highlights

Nemesis Bioscience — Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics.The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.

Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University

Investment focus

Health Care, Apps, Wellness
Seed, Series A, Series B
United States, United Kingdom

Portfolio highlights

OneRoof — OneRoof is an app that helps meet people with similar interests living in your building and build new friendships. Communication should go further than a nod in the elevator.
ShareWell — Struggling with mental health? ShareWell provides online peer support, a proven mental health alternative for therapy. Get group support when you need it.
Bridge Money — The path towards upward economic mobility.

Advisory CTO and Angel Investor

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
United States, India, Canada

Portfolio highlights

SiPhox Health — SiPhox Health brings comprehensive, at-home blood testing to your door! Take control of your disease risk and increase your healthspan today with affordable, convenient at-home blood testing. No lab visits, no appointments, no waiting in line.
Delphi — Delphi is digital cloning that scales time, monetizes knowledge, and interacts audience at scale.
NewHomesMate — Find, compare and buy a new construction home - all in one place.

John Anthony Knight

Investment focus

Software, Life Science, Biotechnology
Seed
United Kingdom

Portfolio highlights

Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.

Siddhant Jayakumar

Investment focus

Biotechnology, Public Safety, Artificial Intelligence
Pre-Seed
United Kingdom

Portfolio highlights

sable bio — We provide comprehensive, quantified, and flexible Target Safety Intelligence to assist toxicologists, informaticians, and drug discovery scientists in delivering safe and effective new treatments.

Andrew Richards is an established biotechnology entrepreneur and investor with extensive experience from the UK biotechnology sector in research, drug development, commercial deals and scale-up of companies.

Investment focus

Biopharma, Education, Biotechnology
Funding Round, Post-IPO Equity
United Kingdom

Portfolio highlights

Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

Investors by industry